AUB ScholarWorks

Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

Show simple item record Mansour A.M. Arevalo J.F. Ziemssen F. Mehio-Sibai A. Mackensen F. Adan A. Chan W.-M. Ness T. Banker A.S. Dodwell D. Chau Tran T.H. Fardeau C. LeHoang P. Mahendradas P. Berrocal M. Tabbarah Z. Hrisomalos N. Hrisomalos F. Al-Salem K. Guth
dc.contributor.editor Aug-2009 2017-10-05T15:49:19Z 2017-10-05T15:49:19Z 2009
dc.identifier 10.1016/j.ajo.2009.03.023
dc.identifier.issn 00029394
dc.description.abstract Purpose: To assess the long-term role of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in inflammatory ocular neovascularization. Design: Retrospective multicenter consecutive case series of inflammatory ocular neovascularization. Methods: settings: Multicenter institutional and private practices. study population: Patients with inflammatory ocular neovascularization in one or both eyes of varying etiologies who failed standard therapy. intervention: Intravitreal injection of bevacizumab. main outcome measures: Improvement of best-corrected visual acuity (BCVA) expressed as logarithm of minimal angle of resolution (logMAR), and decrease in central foveal thickness as measured by optical coherence tomography at 6, 12, 18, and 24 months of follow-up. Results: Mean logMAR BCVA (central foveal thickness) following intravitreal bevacizumab was as follows: baseline, 0.65 (6-27 or 20-90) (338 μm; 99 eyes of 96 patients); 6 months, 0.42 (6-16 or 20-53) (239 μm; 2.0 injections; 81 eyes); 12 months, 0.39 (6-15 or 20-49) (241 μm; 2.3 injections; 95 eyes); 18 months, 0.40 (6-15 or 20-50) (261 μm; 3.0 injections; 46 eyes); and 24 months, 0.34 (6-13 or 20-44) (265 μm; 3.6 injections; 27 eyes). Paired comparisons revealed significant visual improvement at 6 months of 2.4 lines (P = .000), at 12 months of 2.5 lines (P = .000), at 18 months of 2.5 lines (P = .001), and at 24 months of 2.2 lines (P = .013). Paired comparisons revealed significant central foveal flattening at 6 months of 78 μm (P = .000), at 12 months of 85 μm (P = .000), at 18 months of 90 μm (P = .003), and at 24 months of 77 μm (P = .022). Three eyes developed submacular fibrosis and 1 eye submacular hemorrhage. Conclusion: Intravitreal bevacizumab led in the long-term to significant mean visual improvement of ≥2.2 lines and significant foveal flattening in a wide variety of inflammatory ocular diseases without major complications. © 2009 Elsevier Inc. All rights reserved.
dc.format.extent Pages: (310-31600)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: American Journal of Ophthalmology; Publication Year: 2009; Volume: 148; no. 2; Pages: (310-31600);
dc.source Scopus
dc.title Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
dc.type Article
dc.contributor.affiliation Mansour, A.M., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Arevalo, J.F., Clinica Oftalmologica Centro Caracas, University of Los Andes, Caracas, Venezuela
dc.contributor.affiliation Ziemssen, F., Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
dc.contributor.affiliation Mehio-Sibai, A., Department of Epidemiology and Population Health, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Mackensen, F., Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany
dc.contributor.affiliation Adan, A., Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, Spain
dc.contributor.affiliation Chan, W.-M., Department of Ophthalmology, Chinese University of Hong Kong, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
dc.contributor.affiliation Ness, T., University Eye Hospital, Freiburg, Germany
dc.contributor.affiliation Banker, A.S., Banker's Retina Clinic, Laser Center, Ahmedabad, Gujarat, India
dc.contributor.affiliation Dodwell, D., Springfield Eye Clinic, Springfield, IL, United States
dc.contributor.affiliation Chau Tran, T.H., Department of Ophthalmology, Groupe Hospitalier Pitié Salpêtrière, Paris, France
dc.contributor.affiliation Fardeau, C., Department of Ophthalmology, Groupe Hospitalier Pitié Salpêtrière, Paris, France
dc.contributor.affiliation LeHoang, P., Department of Ophthalmology, Groupe Hospitalier Pitié Salpêtrière, Paris, France
dc.contributor.affiliation Mahendradas, P., Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India
dc.contributor.affiliation Berrocal, M., Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico
dc.contributor.affiliation Tabbarah, Z., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Hrisomalos, N., Department of Ophthalmology, Indiana University, Indianapolis, IN, United States
dc.contributor.affiliation Hrisomalos, F., Department of Ophthalmology, Indiana University, Indianapolis, IN, United States
dc.contributor.affiliation Al-Salem, K., Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Guthoff, R., Department of Ophthalmology, University of Wuerzburg, Wuerzburg, Germany
dc.contributor.authorAddress Mansour, A.M.; Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Mansour, AM
dc.contributor.authorInitials Arevalo, JF
dc.contributor.authorInitials Ziemssen, F
dc.contributor.authorInitials Mehio-Sibai, A
dc.contributor.authorInitials Mackensen, F
dc.contributor.authorInitials Adan, A
dc.contributor.authorInitials Chan, WM
dc.contributor.authorInitials Ness, T
dc.contributor.authorInitials Banker, AS
dc.contributor.authorInitials Dodwell, D
dc.contributor.authorInitials Tran, THC
dc.contributor.authorInitials Fardeau, C
dc.contributor.authorInitials Lehoang, P
dc.contributor.authorInitials Mahendradas, P
dc.contributor.authorInitials Berrocal, M
dc.contributor.authorInitials Tabbarah, Z
dc.contributor.authorInitials Hrisomalos, N
dc.contributor.authorInitials Hrisomalos, F
dc.contributor.authorInitials Al-Salem, K
dc.contributor.authorInitials Guthoff, R
dc.contributor.authorReprintAddress Mansour, AM (reprint author), Amer Univ Beirut, Dept Ophthalmol, PO 113-6044, Beirut, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180; Adan A, 2007, GRAEF ARCH CLIN EXP, V245, P1873, DOI 10.1007-s00417-007-0637-y; Ben Yahia Salim, 2008, International Ophthalmology, V28, P311, DOI 10.1007-s10792-008-9218-2; Brown J, 1996, OPHTHALMOLOGY, V103, P1100; CANTRILL HL, 1986, AM J OPHTHALMOL, V101, P170; Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016-j.ajo.2007.02.039; Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001-archopht.126.7.941; Coma MC, 2007, OPHTHALMOLOGY, V114, P1574, DOI 10.1016-j.ophtha.2006.11.028; Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097-IAE.0b013e318187aff9; KLEINER RC, 1988, RETINA-J RET VIT DIS, V8, P225; Kucukerdonmez C, 2008, OCUL IMMUNOL INFLAMM, V16, P63, DOI 10.1080-09273940801923903; Kumar A, 2007, CAN J OPHTHALMOL, V42, P335, DOI 10.3129-canjophthalmol.i07-026; KURUP S, 2008, ACTA OPHTHA IN PRESS; Machida S, 2008, RETINA-J RET VIT DIS, V28, P703, DOI 10.1097-IAE.0b013e318160798f; Mackensen F, 2008, RETINA-J RET VIT DIS, V28, P41, DOI 10.1097-IAE.0b013e318156db75; Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016-j.ajo.2008.05.024; Maruotti N, 2008, CLIN EXP RHEUMATOL, V26, P476; Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097-00006982-200604000-00003; Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097-IAE.0b013e31816576d5; Nowilaty SR, 2006, BRIT J OPHTHALMOL, V90, P982, DOI 10.1136-bjo.2006.091538; PALESTINE AG, 1984, BRIT J OPHTHALMOL, V68, P667, DOI 10.1136-bjo.68.9.667; Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016-j.ajo.2004.03.029; Perentes Y, 2005, OCUL IMMUNOL INFLAMM, V13, P219, DOI 10.1080-09273940490518883; Perentes Y, 2002, KLIN MONATSBL AUGENH, V219, P311, DOI 10.1055-s-2002-30662; Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016-j.ophtha.2004.02.014; Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016-j.ajo.2007.12.030; Shimada H, 2008, JPN J OPHTHALMOL, V52, P282, DOI 10.1007-s10384-008-0566-2; Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007-s00417-008-0906-4; Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007-s00417-003-0734-5; Yang PZ, 2007, OPHTHALMOLOGY, V114, P606, DOI 10.1016-j.ophtha.2006.07.040; Ziemssen F, 2007, GRAEF ARCH CLIN EXP, V245, P917, DOI 10.1007-s00417-006-0512-2
dc.description.citedCount 25
dc.description.citedTotWOSCount 16
dc.description.citedWOSCount 15
dc.format.extentCount 31291
dc.identifier.coden AJOPA
dc.identifier.pubmedID 19427992
dc.identifier.scopusID 67650427145
dc.publisher.address 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
dc.relation.ispartOfISOAbbr Am. J. Ophthalmol.
dc.relation.ispartOfIssue 2
dc.relation.ispartofPubTitle American Journal of Ophthalmology
dc.relation.ispartofPubTitleAbbr Am. J. Ophthalmol.
dc.relation.ispartOfVolume 148
dc.source.ID WOS:000268540300024
dc.type.publication Journal
dc.subject.otherChemCAS bevacizumab, 216974-75-3
dc.subject.otherChemCAS Angiogenesis Inhibitors
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS Vascular Endothelial Growth Factor A
dc.subject.otherChemCAS bevacizumab
dc.subject.otherIndex bevacizumab
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex eye disease
dc.subject.otherIndex eye neovascularization
dc.subject.otherIndex female
dc.subject.otherIndex follow up
dc.subject.otherIndex human
dc.subject.otherIndex inflammatory disease
dc.subject.otherIndex intraocular hypertension
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex ocular fibrosis
dc.subject.otherIndex optical coherence tomography
dc.subject.otherIndex priority journal
dc.subject.otherIndex retina fovea
dc.subject.otherIndex retina macula hemorrhage
dc.subject.otherIndex retrospective study
dc.subject.otherIndex thickness
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex visual acuity
dc.subject.otherIndex Adult
dc.subject.otherIndex Angiogenesis Inhibitors
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Choroidal Neovascularization
dc.subject.otherIndex Choroiditis
dc.subject.otherIndex Female
dc.subject.otherIndex Fluorescein Angiography
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Humans
dc.subject.otherIndex Injections
dc.subject.otherIndex Male
dc.subject.otherIndex Retrospective Studies
dc.subject.otherIndex Tomography, Optical Coherence
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Uveitis
dc.subject.otherIndex Vascular Endothelial Growth Factor A
dc.subject.otherIndex Visual Acuity
dc.subject.otherIndex Vitreous Body
dc.subject.otherKeywordPlus PUNCTATE INNER CHOROIDOPATHY
dc.subject.otherKeywordPlus UVEITIC MACULAR EDEMA
dc.subject.otherKeywordPlus MULTIFOCAL CHOROIDITIS
dc.subject.otherKeywordPlus PHOTODYNAMIC THERAPY
dc.subject.otherKeywordPlus EALES-DISEASE
dc.subject.otherKeywordPlus HISTOPLASMOSIS SYNDROME
dc.subject.otherKeywordPlus CHORIORETINAL DISEASES
dc.subject.otherKeywordPlus AVASTIN
dc.subject.otherWOS Ophthalmology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account